Radiochemical separation and purification of promethium-149 radioisotope from irradiated of neodymium oxide target (98.4% of 148Nd enrichment) based on extraction chromatography method

Cancer is the second leading cause of death globally and increasing every year, including in Indonesia. Promethium-149 (149Pm) one beta-emitting (Eβ-max 1.07 MeV T1/2 2.21 days) radiolanthanides that can be used for therapeutic application. Radioisotope 149Pm produced with high specific activity was suitable labeling biomolecule as a targeted radiopharmaceutical cancer therapy. Radiochemical separation from irradiated neodymium oxide (Nd2O3) target 98.4% neodymium-148 (148Nd) isotope enrichment has been carried out based on extraction chromatography method using LN (Eichrom) resin column. The material at Bandung TRIGA 2000 reactor. purity final product 149PmCl3 radioisotope determined paper electrophoresis methods. Radionuclide solution gamma-ray spectrometer equipped HP-Ge detector multichannel analyzer (MCA). results show optimum condition Nd2O3 148Nd obtained 1.5N HNO3 temperature 80 °C mobile phase. yield 97.8 ± 2.1%. physico-chemical characteristic meet requirements nuclear medicine applications radiochemical radionuclide 99.7 0.2% 99.9 0.1%, respectively. clear, pH 1 stable 1.5 weeks room temperature.